Company intelligence / Profile preview

Promark Holdings

Rockville, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Promark Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing proprietary formulations of established metabolic drugs to improve patient outcomes. The company's lead candidate, PM-101, is a proprietary formulation of metformin designed to optimize the drug's pharmacokinetic profile for the treatment of type 2 diabetes. Promark aims to address unmet needs in metabolic disease management by enhancing the efficacy and tolerability of standard-of-care therapies. The company is headquartered in Rockville, Maryland, and operates within the broader metabolic and endocrine therapeutic space.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecule
Industry: Investors

Beyond the preview

Go deeper on Promark Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Promark Holdings.

Explore the full profile